Bristol-Myers Squibb | BMY - Debt



Bristol-Myers Squibb reported $50.93B in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Abbott USD 13.44B 195M Jun/2025
ALKERMES USD 72.68M 72.68M Jun/2025
Amgen USD 56.2B 1.18B Jun/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
Biogen USD 6.59B 296.8M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Drreddys Laboratories INR 48.64B 2.44B Jun/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
GlaxoSmithKline GBP 17.35B 1.08B Jun/2025
J&J USD 52.25B 15.62B Mar/2025
Medtronic USD 28.52B 1.91B Apr/2025
Merck USD 34.84B 2.27B Mar/2025
Novartis USD 31.27B 12M Mar/2025
Novo Nordisk 118.72B 61.75B Mar/2025
Perrigo USD 3.65B 24.4M Jun/2025
Pfizer USD 60.93B 1.18B Jun/2025
Prestige Brands USD 1.04B 27.25M Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Roche Holding CHF 34.44B 5.23B Jun/2024
Sanofi 22.28B 1.24B Jun/2025
Sanofi 22.28B 4.38B Jun/2025
United Therapeutics USD 200M 100M Mar/2025
Zoetis USD 6.79B 214M Jun/2025